Sichuan Kelun-Biotech Biopharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Sichuan Kelun-Biotech Biopharmaceutical has a total shareholder equity of CN¥3.2B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥3.8B and CN¥625.5M respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
CN¥0
Schuld
| Rente dekkingsratio | n/a |
| Contant | CN¥2.89b |
| Aandelen | CN¥3.21b |
| Totaal verplichtingen | CN¥625.51m |
| Totaal activa | CN¥3.83b |
Recente financiële gezondheidsupdates
Recent updates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 21
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Jun 14Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued
Jan 11Analyse van de financiële positie
Kortlopende schulden: 6990's short term assets (CN¥3.2B) exceed its short term liabilities (CN¥553.8M).
Langlopende schulden: 6990's short term assets (CN¥3.2B) exceed its long term liabilities (CN¥71.7M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 6990 is debt free.
Schuld verminderen: 6990 had no debt 5 years ago.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: 6990 has sufficient cash runway for more than 3 years based on its current free cash flow.
Voorspelling contante baan: Insufficient data to determine if 6990 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.